A securities class action has been filed against Eiger BioPharmaceuticals, Inc. (EIGR) on behalf of a class consisting of all persons who purchased the Company’s securities between March 10, 2021 through October 4, 2022. This case has been filed in the USDC – N.D.CA.
According to the Complaint, the Company made false and misleading statements to the market. Eiger overstated its expertise in regulatory drug development to investors. The Company failed to properly assess problems with its TOGETHER trial and determine if the trial could support the peginterferon lambda EUA. Based on these problems with the trial, the FDA was unlikely to approve the Company’s EUA. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Eiger, investors suffered damages.